Certara Products - Simcyp Archives | Page 21 of 22

Publication

Application of PBPK Modeling to Predict Monoclonal Antibody Disposition in Plasma and Tissues in Mouse Models of Human Colorectal Cancer

This investigation evaluated the utility of a physiologically based pharmacokinetic (PBPK) model, which incorporates model…

CertaraDecember 1, 2012

Publication

A Pregnancy Physiologically-based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4, and CYP2D6

Pregnant women are usually not part of the traditional drug development program. Pregnancy is associated…

CertaraOctober 9, 2012

Publication

Physiologically-based Modeling of Pravastatin Transporter-mediated Hepatobiliary Disposition and Drug-drug Interactions

To develop physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and drug-drug interactions (DDI)…

CertaraOctober 1, 2012

Publication

Physiologically-based Pharmacokinetic (PBPK) Models for Assessing the Kinetics of Xenobiotics During Pregnancy: Achievements and Shortcomings

The physiological changes that occur in the maternal body and the placental-foetal unit during pregnancy…

CertaraJuly 1, 2012

Publication

From Pre-clinical to Human—Prediction of Oral Absorption and Drug-drug Interaction Potential Using Physiologically-based Pharmacokinetic (PBPK) Modeling Approach in an Industrial Setting: A Workflow by Using Case Example

A case example is presented in which the physiologically based modeling approach has been used…

CertaraMarch 1, 2012

Publication

Physiologically-based PharmacoKinetic (PBPK) Modeling Tools: How to Fit with Our Needs?

In 2005, a survey compared a number of commercial PBPK software available at the time,…

CertaraMarch 1, 2012

Publication

Using Simcyp to Project Human Oral Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-based Adverse Events

Positive allosteric modulators ('potentiators') of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) have been shown to display…

CertaraMarch 1, 2012

Publication

Physiologically-based Pharmacokinetic Model for Topotecan in Mice

Topotecan is a chemotherapeutic agent of choice for the second-line treatment of recurrent ovarian cancer.…

CertaraFebruary 1, 2011

Publication

Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science

The application of physiologically-based pharmacokinetic (PBPK) modeling is coming of age in drug development and…

CertaraFebruary 1, 2011

Publication

PBPK Modeling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals

Generic PBPK models, applicable to a large number of substances, coupled to parameter databases and…

CertaraDecember 30, 2010

Certara Products – Simcyp

Application of PBPK Modeling to Predict Monoclonal Antibody Disposition in Plasma and Tissues in Mouse Models of Human Colorectal Cancer

A Pregnancy Physiologically-based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4, and CYP2D6

Physiologically-based Modeling of Pravastatin Transporter-mediated Hepatobiliary Disposition and Drug-drug Interactions

Physiologically-based Pharmacokinetic (PBPK) Models for Assessing the Kinetics of Xenobiotics During Pregnancy: Achievements and Shortcomings

From Pre-clinical to Human—Prediction of Oral Absorption and Drug-drug Interaction Potential Using Physiologically-based Pharmacokinetic (PBPK) Modeling Approach in an Industrial Setting: A Workflow by Using Case Example

Physiologically-based PharmacoKinetic (PBPK) Modeling Tools: How to Fit with Our Needs?

Using Simcyp to Project Human Oral Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-based Adverse Events

Physiologically-based Pharmacokinetic Model for Topotecan in Mice

Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science

PBPK Modeling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals

Newsletter sign up

Quick links

Solutions

Contact